Citigroup
HELX icon

Citigroup’s Franklin Genomic Advancements ETF HELX Stock Holding History

Citigroup’s Portfolio HELX Stock Details HELX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15
Closed -$491 – 5663
2024
Q1 		$491 Buy
+15
New +$469 ﹤0.01% 5459

Other funds holding HELX

GT
Glenview Trust Louisville, Kentucky $6.37B AUM 23.72% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup's HELX Position: Q2 2024 in Review

Citigroup sold out of Franklin Genomic Advancements ETF (HELX) in Q2 2024, closing a stake of 15 shares — an estimated $491 sold.

Citigroup first reported a position in HELX in Q1 2024 and held it in 1 quarter. The position peaked at $491 in Q1 2024. 7 funds tracked by Wall St. Rank hold HELX as of Q2 2024.

  • Citigroup reported no remaining Franklin Genomic Advancements ETF position as of Q2 2024 after selling out during the quarter.
  • Citigroup sold 15 Franklin Genomic Advancements ETF shares in Q2 2024, an estimated $491.
  • Citigroup first reported a position in Franklin Genomic Advancements ETF in Q1 2024 and held it in 1 quarter.
  • Citigroup's Franklin Genomic Advancements ETF position peaked at $491 in Q1 2024.
  • 7 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q2 2024.

Based on Citigroup's 13F filing for Q2 2024, filed 12 Aug 2024.